- Home
- JUNS vs DMAC Comparison
JUNS vs DMAC Comparison
Compare JUNS & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JUNS
- DMAC
- Stock Information
- Founded
- JUNS 2015
- DMAC 2000
- Country
- JUNS United States
- DMAC United States
- Employees
- JUNS N/A
- DMAC N/A
- Industry
- JUNS
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- JUNS
- DMAC Health Care
- Exchange
- JUNS NYSE
- DMAC Nasdaq
- Market Cap
- JUNS 281.4M
- DMAC 267.7M
- IPO Year
- JUNS 2024
- DMAC N/A
- Fundamental
- Price
- JUNS $0.75
- DMAC $4.73
- Analyst Decision
- JUNS
- DMAC Strong Buy
- Analyst Count
- JUNS 0
- DMAC 3
- Target Price
- JUNS N/A
- DMAC $8.00
- AVG Volume (30 Days)
- JUNS 149.3K
- DMAC 69.8K
- Earning Date
- JUNS 05-11-2025
- DMAC 03-17-2025
- Dividend Yield
- JUNS N/A
- DMAC N/A
- EPS Growth
- JUNS N/A
- DMAC N/A
- EPS
- JUNS N/A
- DMAC N/A
- Revenue
- JUNS N/A
- DMAC N/A
- Revenue This Year
- JUNS N/A
- DMAC N/A
- Revenue Next Year
- JUNS N/A
- DMAC N/A
- P/E Ratio
- JUNS N/A
- DMAC N/A
- Revenue Growth
- JUNS N/A
- DMAC N/A
- 52 Week Low
- JUNS $0.55
- DMAC $2.14
- 52 Week High
- JUNS $19.51
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- JUNS N/A
- DMAC 33.69
- Support Level
- JUNS N/A
- DMAC $5.49
- Resistance Level
- JUNS N/A
- DMAC $5.12
- Average True Range (ATR)
- JUNS 0.00
- DMAC 0.33
- MACD
- JUNS 0.00
- DMAC -0.10
- Stochastic Oscillator
- JUNS 0.00
- DMAC 4.15
About JUNS JUPITER NEUROSCIENCES INC
Jupiter Neurosciences Inc is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to most central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.